Compare HNVR & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | CNTN |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 146.5M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | CNTN |
|---|---|---|
| Price | $26.81 | $2.22 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $24.50 | N/A |
| AVG Volume (30 Days) | 47.0K | ★ 675.0K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $33.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.75 |
| 52 Week High | $27.89 | $5.27 |
| Indicator | HNVR | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 60.11 |
| Support Level | $22.61 | $2.14 |
| Resistance Level | $27.89 | $3.80 |
| Average True Range (ATR) | 0.61 | 0.13 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 63.64 | 90.99 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.